Anwulignan Alleviates Bone Cancer Pain by Modulating the <scp>PPARα</scp>/<scp>CXCR2</scp> Signaling Pathway in the Rat Spinal Cord
Taken together, these results indicate that Anwulignan is a potential antitumor and analgesic agent that exerts its effects via upregulation of PPARα expression to inhibit the expression of CXCR2 and could be used for treating BCP.
Authors
- Jing Cao (ORCID: https://orcid.org/0000-0003-3124-4780)
- Yingying Jiang (ORCID: https://orcid.org/0000-0002-3688-1052)
- Huilian Bu
- Jingjing Yuan (ORCID: https://orcid.org/0000-0002-3144-6123)
- Qingying Liu (ORCID: https://orcid.org/0000-0002-5954-1958)
- Minyu Ma (ORCID: https://orcid.org/0000-0002-5569-608X)
- Xiaochong Fan (ORCID: https://orcid.org/0000-0002-6640-2665)
- Jian Wang (ORCID: https://orcid.org/0000-0003-2291-640X)
- Longfei Mao (ORCID: https://orcid.org/0000-0002-4514-7888)
- Yueliang Wang
- Mohamed Zoubaa
Institutions
- Henan University of Science and Technology (CN)
- Capital Medical University (CN)
- Zhengzhou University (CN)
- Beijing Institute of Neurosurgery (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/cns.70302
- Citations
- 2
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- National Natural Science Foundation of China